Abstract | OBJECTIVE: PATIENTS AND METHODS: We undertook a prospective study of 29 kidney transplant recipients with HPT who started treatment with 30 mg of cinacalcet. The mean follow-up was 13 months (range, 3-29 months). RESULTS: Treatment with cinacalcet effectively reduced levels of calcium (baseline, 11.1 +/- 0.8 vs 9.7 +/- 0.6 mg/dL at 12 months; P < .05) and intact parathyroid hormone (iPTH; baseline, 288 +/- 155 vs 236 +/- 118 pg/mL at 12 months; P = NS). Phosphorus levels increased from 2.5 +/- 0.6 to 3.2 +/- 0.8 mg/dL (P < .05). The mean dose of cinacalcet was 60 mg (range, 30-120 mg). Two patients required parathyroidectomy. Cinacalcet was well tolerated, except in 2 patients who had nausea and epigastralgia. CONCLUSIONS:
Cinacalcet was safe and effective in kidney transplant patients with hypercalcemia secondary to HPT. Of note was the low incidence of adverse side effects despite the high doses prescribed for these patients.
|
Authors | V López, R Toledo, E Sola, C Gutiérrez, S Sujan, M A Rodríguez, M Cabello, D Burgos, M González Molina, D Hernández |
Journal | Transplantation proceedings
(Transplant Proc)
2009 Jul-Aug
Vol. 41
Issue 6
Pg. 2394-5
ISSN: 1873-2623 [Electronic] United States |
PMID | 19715930
(Publication Type: Journal Article)
|
Chemical References |
- Immunosuppressive Agents
- Naphthalenes
- Cinacalcet
|
Topics |
- Adult
- Aged
- Cinacalcet
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Humans
- Hypercalcemia
(drug therapy, etiology)
- Hyperparathyroidism, Secondary
(drug therapy, etiology, surgery)
- Immunosuppressive Agents
(therapeutic use)
- Kidney Transplantation
(adverse effects, immunology)
- Male
- Middle Aged
- Naphthalenes
(administration & dosage, therapeutic use)
- Parathyroidectomy
- Prospective Studies
- Time Factors
|